VIP (Vasoactive Intestinal Peptide): What the Research Shows

The vasoactive intestinal peptide with one real human trial — and a fundamental mismatch between clinical evidence and community use

Vasoactive Intestinal Peptide occupies a peculiar position in peptide research: it is simultaneously one of the most extensively studied neuropeptides in basic science, with a literature spanning five decades and thousands of publications, and one of the least developed therapeutically, with no approved systemic applications despite decades of research interest. The gap between VIP’s rich biological profile and its thin therapeutic track record tells a story that is more about the pharmacological challenges of working with this class of molecule than about any failure of the underlying science.

VIP is a 28-amino-acid endogenous neuropeptide present throughout the human body—in the nervous system, the gut, the lungs, the immune system, and the reproductive tract. It acts primarily through two G-protein-coupled receptors, VPAC1 and VPAC2, producing effects that span vasodilation, smooth muscle relaxation, immune modulation, neuronal activity, and circadian rhythm regulation. The breadth of its biological activity is both its most interesting pharmacological feature and one of the central challenges to developing it as a targeted therapeutic.

In self-experimentation communities, VIP is discussed primarily in the context of chronic inflammatory response syndrome (CIRS) associated with biotoxin exposure, and as an anti-inflammatory adjunct in general recovery contexts. This article covers the full evidence base: what VIP actually does in human biology, what the research record shows across inflammation, injury recovery, and pulmonary applications, why therapeutic development has been slow, and what that means for evaluating community claims.

Quick Facts

Peptide Name	VIP (Vasoactive Intestinal Peptide; also Vasoactive Intestinal Polypeptide)
Type	Endogenous neuropeptide and neuroimmune mediator; member of the secretin/glucagon superfamily
Amino Acid Length	28 amino acids
Molecular Weight	~3,326 g/mol
Primary Receptors	VPAC1 (ubiquitously expressed); VPAC2 (CNS, smooth muscle, immune cells); both Gs-coupled GPCRs activating adenylyl cyclase
Primary Expression Sites	Enteric nervous system; CNS neurons; peripheral nervous system; T cells and immune cells; lungs; hypothalamic suprachiasmatic nucleus
Primary Research Areas	Inflammatory bowel disease, rheumatoid arthritis, pulmonary arterial hypertension, sepsis, neuroinflammation, circadian disorders
Regulatory Status	Not approved for systemic therapeutic use; Aviptadil (inhaled/IV VIP) investigated for PAH and COVID-19 ARDS without achieving regulatory approval
WADA Status	Not prohibited
Evidence Tier	PRECLINICAL ONLY  for injury recovery and general use; limited human trial data for specific pulmonary and RA indications only

---

What Is VIP?

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily—a group of structurally related peptides sharing a common evolutionary origin and similar receptor binding characteristics. It is produced throughout the body, most abundantly in the enteric nervous system of the gut, the central and peripheral nervous systems, and immune cells, particularly T lymphocytes. Its name reflects its initial characterization: identified for its potent vasodilatory and intestinal smooth muscle-relaxing effects when first isolated from porcine small intestine in 1970.

VIP acts through two receptor subtypes—VPAC1 and VPAC2—both G-protein-coupled receptors that signal through adenylyl cyclase to raise intracellular cAMP. VPAC1 is expressed broadly across many tissue types; VPAC2 has a more restricted expression pattern in the central nervous system, smooth muscle, and immune cells. This receptor distribution explains why VIP has such diverse physiological effects: it is simultaneously a gut motility regulator, a pulmonary vasodilator, an immune modulator, a circadian rhythm synchronizer, and a neuroprotective signaling molecule.

As a research compound, VIP is available through peptide suppliers. The most clinically developed VIP application is inhaled VIP (Aviptadil, developed by NeuroRx) for pulmonary arterial hypertension and COVID-19-associated ARDS—applications that leverage VIP’s pulmonary vasodilatory effects and ability to suppress cytokine-driven pulmonary inflammation. These clinical applications involve specific inhalation or IV formulations targeting the lungs or critical care contexts—a very different pharmacological situation from systemic subcutaneous injection.

In the self-experimentation community, VIP is discussed primarily in the context of chronic inflammatory response syndrome (CIRS) associated with biotoxin exposure, and as a general anti-inflammatory compound. Both applications require careful evidence evaluation, as they involve either a contested diagnostic framework or extrapolation from basic science and limited clinical data to a very different route of administration.

---

Origins and Discovery

VIP was discovered in 1970 by Sami Said and Viktor Mutt at the Karolinska Institute in Stockholm, who isolated it from porcine small intestine while characterizing bioactive peptides in intestinal extracts. The name “vasoactive intestinal peptide” reflected its two most striking initial properties: origin in intestinal tissue and potent vasodilatory effect when injected into blood vessels. Said and Mutt’s original report described a peptide causing profound hypotension in animal preparations.

The full amino acid sequence was determined in 1972, and VIP was subsequently identified in the nervous system using immunohistochemical techniques—VIP-containing neurons were found throughout the enteric and central nervous systems. The discovery that VIP was not only a gut hormone but a neuropeptide substantially expanded understanding of its biological role. VIP neurons were identified in the hypothalamus, cortex, hippocampus, and throughout the peripheral nervous system.

The cloning of VIP receptors—VPAC1 in 1994 and VPAC2 in 1995—provided molecular tools to dissect these diverse effects. The subsequent discovery of VIP’s immunomodulatory effects in the 1990s and early 2000s—particularly its ability to suppress pro-inflammatory cytokines and promote regulatory T-cell activity—generated significant research interest in its therapeutic potential for autoimmune and inflammatory diseases. This work, largely conducted by Mario Delgado, Doina Ganea, and their collaborators, established VIP as one of the most potent endogenous anti-inflammatory neuropeptides.

---

VIP in Human Biology: Distribution and Physiological Roles

VIP’s pharmacology requires appreciating the breadth of its endogenous distribution and function. It is not a peptide with a single, circumscribed biological role—it is a pleiotropic signaling molecule participating in the regulation of multiple organ systems simultaneously.

Gut and Enteric Nervous System

VIP is the most abundant neuropeptide in the enteric nervous system. In the gut, VIP neurons are inhibitory motor neurons that relax smooth muscle and promote gut motility. VIP is also a potent secretagogue in the intestine, stimulating water and electrolyte secretion into the gut lumen. The clinical significance of VIP in the gut is illustrated by VIPomas—rare neuroendocrine tumors that secrete large amounts of VIP. VIPoma patients develop Verner-Morrison syndrome (WDHA syndrome): profuse watery diarrhea, dehydration, and electrolyte disturbances. This syndrome makes clear that sustained high VIP levels produce significant adverse effects—a relevant consideration for anyone contemplating exogenous administration.

Cardiovascular and Pulmonary System

VIP is a potent vasodilator, acting on smooth muscle in blood vessel walls through VPAC1 and VPAC2 to increase cAMP and promote muscle relaxation. In the lungs specifically, VIP is a major endogenous regulator of pulmonary vascular tone, and VIP deficiency has been documented in pulmonary arterial hypertension patients. This pulmonary vasodilation is the basis for the most clinically developed VIP application (Aviptadil for PAH), but it also means systemic VIP administration produces hypotension as a predictable adverse effect.

Immune System

VIP is produced by T lymphocytes and acts as an autocrine and paracrine immune regulator. Its immunological effects are predominantly anti-inflammatory: it suppresses production of TNF-alpha, IL-6, IL-12, and IFN-gamma; promotes regulatory T-cell (Treg) differentiation; inhibits Th1 and Th17 immune responses that drive many autoimmune conditions; and shifts macrophage polarization toward anti-inflammatory M2 phenotypes. This neuroimmune connection—VIP released by neurons at sites of tissue injury—provides a molecular link between nervous system signaling and immune regulation.

Circadian System

VIP plays a critical role in coordinating circadian rhythms. In the hypothalamic suprachiasmatic nucleus (SCN)—the brain’s master circadian clock—VIP is the primary synchronizing signal between individual oscillator neurons. VIP-deficient mice show severe circadian rhythm disruption, losing coordinated daily cycles in activity, temperature, hormone secretion, and immune function. This role has implications for VIP’s effects on sleep, hormone regulation, and the timing of immune responses—and for the potential consequences of exogenous VIP on circadian function depending on timing of administration.

---

Mechanism of Action

VIP acts through VPAC1 and VPAC2—two receptors sharing approximately 50% sequence homology, both coupling to Gs proteins to activate adenylyl cyclase and raise intracellular cAMP. Despite this shared signaling mechanism, their distinct tissue distributions produce distinct functional roles.

VPAC1/VPAC2 Signaling and Anti-Inflammatory Downstream Effects

In immune cells, cAMP/PKA signaling downstream of VPAC1/2 activation inhibits NF-kB nuclear translocation, reduces MAPK pathway activation, and activates CREB—a transcription factor driving expression of anti-inflammatory mediators. The net result is suppression of pro-inflammatory cytokine gene expression and promotion of anti-inflammatory programs including IL-10 production and Treg differentiation. In smooth muscle, cAMP/PKA activation reduces contraction, producing the vasodilatory and bronchodilatory effects that define VIP’s original pharmacological characterization.

Regulatory T-Cell Induction

One of VIP’s most pharmacologically important immunological effects is its ability to promote Treg differentiation. Tregs suppress excessive immune responses and maintain self-tolerance; their deficiency or dysfunction is implicated in multiple autoimmune conditions. VIP stimulates Treg differentiation both directly—acting on T cells via VPAC1—and indirectly, by inducing tolerogenic dendritic cell phenotypes that favor Treg generation. This Treg-inducing property is mechanistically central to VIP’s potential in autoimmune disease research and was confirmed to operate in humans in the Phase II RA trial, where VIP treatment increased circulating Treg numbers.

The Short Half-Life Problem

VIP has a very short plasma half-life—estimated at 1-2 minutes following intravenous administration. This rapid clearance is primarily due to degradation by neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP-IV). The consequence is that bolus injection produces a brief pulse of activity rather than sustained receptor engagement. This pharmacokinetic limitation is a major obstacle to therapeutic development and is one reason the human RA trial used prolonged IV infusion rather than bolus injection. Subcutaneous injection produces a somewhat slower absorption profile but does not overcome the fundamental rapid degradation issue. Whether brief exposure from subcutaneous bolus injection achieves the sustained Treg induction observed with prolonged IV infusion is pharmacokinetically uncertain.

---

Key Research Areas and Studies

Rheumatoid Arthritis: The Key Human Trial

VIP has been studied in rheumatoid arthritis both preclinically and in a small human trial—the most important clinical data point for evaluating VIP’s anti-inflammatory potential in humans. In mouse models of collagen-induced and adjuvant-induced arthritis, VIP produced significant reductions in joint inflammation, pannus formation, and bone destruction through Treg induction and Th17 suppression.

The Phase II clinical trial (Jimeno et al., 2010) enrolled 40 patients with active RA and randomized them to receive VIP infusion or placebo over 12 weeks. The VIP-treated group showed statistically significant improvements in disease activity scores (DAS28), tender and swollen joint counts, inflammatory markers (CRP, ESR), and quality of life measures. Importantly, VIP treatment increased circulating Treg numbers—confirming that the Treg-induction mechanism observed preclinically operates in humans. Hypotension was the most common adverse event.

This trial is the most clinically significant human study of VIP as an anti-inflammatory therapeutic. It was small, single-center, and requires replication in larger cohorts before definitive conclusions can be drawn. But it represents genuine controlled human evidence—a distinction that separates VIP from the purely preclinical compounds in this cluster.

Inflammatory Bowel Disease

VIP’s anti-inflammatory immunology and endogenous role in the enteric nervous system make IBD a natural research focus. In DSS, TNBS, and adoptive transfer colitis models, VIP treatment has consistently shown reductions in mucosal inflammation, lower cytokine levels, improved epithelial barrier function, and Treg induction. Despite this substantial preclinical record, no Phase II trial of VIP specifically for IBD has been completed and published. Key obstacles include the short half-life requiring continuous delivery, the competitive landscape of IBD biologics, and the off-target cardiovascular effects that complicate systemic dosing.

Pulmonary Arterial Hypertension and Aviptadil

VIP deficiency has been documented in PAH patients—reduced plasma VIP levels, reduced VIP expression in pulmonary vascular tissue—providing a biological rationale for supplementation. Clinical trials of inhaled VIP in PAH showed improvements in pulmonary hemodynamics and exercise capacity. NeuroRx developed Aviptadil for PAH and subsequently investigated it for COVID-19 ARDS. COVID-19 trials showed preliminary positive signals for survival in some analyses, but the data had methodological limitations and FDA did not grant Emergency Use Authorization. The application of Aviptadil as a critical care IV infusion for ARDS is distinct from subcutaneous self-experimentation and should not be conflated.

Injury Recovery Applications

VIP’s relevance to injury recovery operates primarily through its anti-inflammatory and vasodilatory mechanisms rather than direct tissue repair pathways. By suppressing pro-inflammatory cytokines, promoting M2 macrophage polarization, and inducing Tregs that limit inflammatory overshoot, VIP may support the transition from inflammatory to reparative healing phases. The vasodilatory effect may improve local perfusion at injury sites, supporting oxygen and nutrient delivery to healing tissue.

Direct injury-specific preclinical studies for VIP (tendon, muscle, bone) are limited compared to the IBD and arthritis literature. The injury recovery application in self-experimentation communities is primarily extrapolated from anti-inflammatory and vasodilatory biology rather than being supported by injury-specific data. This is an important distinction from BPC-157, where extensive injury-specific preclinical evidence exists.

Neurological Applications

VIP’s neuroprotective and neurotrophic properties have been investigated in models of Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and multiple sclerosis. These models show VIP or PACAP (pituitary adenylate cyclase-activating polypeptide, sharing VIP receptors) treatment reduces neuroinflammation and supports neuronal survival. Central nervous system delivery presents additional challenges—the blood-brain barrier limits peripheral VIP’s CNS penetration, making systemic administration less effective for central neuroprotection. Intranasal delivery has been explored as a CNS bypass route with some preclinical support but no human data.

---

VIP and CIRS: Separating Science from Community Claims

The most prominent community use context for VIP involves chronic inflammatory response syndrome (CIRS)—a diagnosis developed and championed primarily by Ritchie Shoemaker, MD. Understanding this context requires clarity about what CIRS is, what the science supports, and where claims exceed the evidence.

Ritchie Shoemaker’s CIRS framework proposes that biotoxin exposure (from water-damaged buildings, Lyme disease, ciguatera toxin, and other sources) triggers a multi-system inflammatory response in genetically susceptible individuals, characterized by dysregulation of multiple biomarkers including VIP levels. VIP nasal spray (50 mcg per dose, administered intranasally, 4x daily) is a final step in the Shoemaker treatment protocol intended to restore VIP levels and normalize downstream signaling.

The biological plausibility underlying this framework is genuine. VIP deficiency has been documented in certain chronic inflammatory conditions. The immunomodulatory effects of VIP are well-characterized. The argument that biotoxin-triggered inflammation could dysregulate the neuroimmune system in ways that include VIP suppression is mechanistically coherent. What is absent is independent validation in controlled trials. The published literature supporting VIP nasal spray for CIRS consists primarily of observational data and case series from Shoemaker’s practice, not controlled trials. The diagnostic tests used have not been validated as markers of the proposed syndrome in independent populations.

Intranasal VIP delivery presents its own pharmacokinetic questions. The nasal mucosa is a reasonable route for some neuropeptides to reach the CNS, but the dose, absorption, and systemic exposure from Shoemaker’s protocol have not been rigorously characterized. The CIRS application of VIP is not supported by clinical trial evidence and should not be presented as such. That assessment does not foreclose the possibility that VIP is biologically active via intranasal administration—it means readers should understand they are working within an unvalidated framework.

---

Common Claims versus Current Evidence

Claim	Current Evidence
“Reduces inflammation systemically”	Extensively supported in preclinical models. The Phase II RA trial provides human evidence of anti-inflammatory effects in a controlled setting—IV infusion over 12 weeks. Pharmacokinetic constraints (very short half-life) limit sustained systemic exposure from subcutaneous bolus injection; whether this route achieves meaningful Treg induction is not validated in humans.
“Treats CIRS and mold illness”	Not supported by controlled clinical trial evidence. CIRS is not a mainstream recognized diagnosis. The VIP nasal spray protocol was developed and promoted by a single researcher without independent validation. The underlying biology is plausible; the clinical evidence base does not meet the standard of controlled research.
“Helps with recovery and healing”	Plausible via anti-inflammatory and vasodilatory mechanisms. No injury-specific human data. The recovery application extrapolates from general anti-inflammatory biology rather than injury-focused research—a different and weaker evidentiary basis than BPC-157’s injury model evidence.
“Treats COVID-19 or ARDS”	Aviptadil (IV/inhaled VIP) showed preliminary positive signals in COVID-19 ARDS trials. FDA did not grant Emergency Use Authorization; trial data had methodological limitations. This is a critical care IV application—it does not support or validate subcutaneous self-administration of research-grade VIP for viral infections.
“Neuroprotective and brain-beneficial”	Supported in preclinical neurodegeneration models. Blood-brain barrier limits peripheral VIP’s CNS penetration, meaning systemic injection may not produce meaningful central neuroprotective effects. Intranasal delivery is explored as a CNS bypass but human data is absent. Claims about cognitive benefits from SC injection lack supporting evidence.

---

The Human Evidence Landscape

VIP’s human evidence situation is more nuanced than the purely preclinical compounds in this cluster, but requires careful interpretation.

What human evidence exists: The Phase II RA trial (Jimeno et al., 2010) is a genuine controlled human study showing anti-inflammatory efficacy via IV infusion—the only such study for VIP’s immunological applications. It was small (n=40), single-center, and requires replication. The Aviptadil PAH and COVID-19 ARDS trials provide additional human data for specific formulations in specific respiratory indications.

The formulation gap: The Aviptadil clinical data involves a specific inhaled or IV formulation for pulmonary or critical care use. The RA trial used prolonged IV infusion over 12 weeks. Neither is the same as subcutaneous injection of research-grade VIP. Extrapolating from these results to subcutaneous self-experimentation assumes pharmacological equivalence across very different delivery systems—an assumption not supported by pharmacokinetic data.

What human evidence does not exist: No controlled human trials of VIP for injury recovery, gut health (despite extensive IBD preclinical data), CIRS, neurological applications, or general anti-inflammatory use via subcutaneous injection. No human pharmacokinetic characterization of subcutaneous VIP at self-experimentation doses.

The net assessment: VIP has more human evidence than KPV or LL-37 but substantially less than Thymosin Alpha-1, and the human evidence that exists is for routes and formulations different from self-experimentation practice. The preclinical tier designation reflects this accurately.

---

Safety, Risks, and Limitations

Hypotension: The Primary Acute Concern

Gastrointestinal Effects

VIP is a potent intestinal secretagogue stimulating water and electrolyte secretion. The VIPoma syndrome—where tumor-secreted VIP causes profuse secretory diarrhea—illustrates the GI consequences of sustained high VIP exposure. At lower research doses, nausea, increased gut motility, and loose stools are commonly reported. These are mechanistically expected effects of VIP’s enteric nervous system actions.

Immunosuppression Considerations

VIP’s Treg-inducing and Th1/Th17-suppressive effects are its therapeutic mechanism—but they also represent a potential concern with chronic use. Sustained suppression of Th1 and Th17 immunity could theoretically impair host defense against intracellular pathogens, fungi, and certain bacteria that require these immune responses for clearance. At the doses and durations of self-experimentation, whether this concern is clinically meaningful is unknown.

Circadian Effects

VIP coordinates circadian rhythms in the suprachiasmatic nucleus. Exogenous VIP administration at times or doses differing from normal physiological patterns could potentially disrupt circadian coordination. The magnitude of this concern depends on timing of administration and baseline circadian state—a complexity that has not been characterized in human studies.

Short Half-Life and Pharmacokinetic Uncertainty

The 1-2 minute IV half-life means bolus injection produces a brief spike of VIP exposure followed by rapid degradation. Whether this produces transient adverse effects (hypotension, flushing, GI effects) without sufficient sustained therapeutic receptor engagement is a genuine pharmacokinetic concern. The brief exposure window from SC injection may not replicate the anti-inflammatory effects observed with prolonged IV infusion in the RA trial.

---

Legal and Regulatory Status

United States

VIP (as a compounded nasal spray) has been evaluated on the FDA’s bulk drug substance list for compounding. Compounding pharmacies have supplied VIP nasal spray primarily for CIRS protocol use. This regulatory status is subject to ongoing FDA evaluation and may change. Aviptadil has been under FDA review without receiving approval or EUA. Research-grade VIP from peptide suppliers operates in a separate regulatory context.

International and WADA

VIP is not approved for systemic therapeutic use in any major international jurisdiction. WADA does not prohibit VIP. Athletes subject to anti-doping testing should verify current status against the annual prohibited list.

---

Research Protocols and Laboratory Practices

Form and Reconstitution

Synthetic VIP is supplied as a lyophilized powder. It is a hydrophilic peptide that dissolves readily in sterile water or PBS. Because VIP is degraded by plasma peptidases (NEP/CD10 and DPP-IV), reconstituted solutions should be used promptly. Peptidase inhibitors are sometimes added in vitro research but are not appropriate for in vivo administration. Standard endotoxin testing of supplier preparations applies for injectable applications.

Storage

Lyophilized VIP is stable at 2-8°C (35-46°F) and may be stored at -20°C (-4°F) for extended periods. Reconstituted solutions should be used immediately or stored at 4°C for no more than 24 hours. Multiple freeze-thaw cycles accelerate degradation. Protect from light.

Routes in Research

Clinical studies have used IV infusion (RA trial, Aviptadil COVID-19), inhalation (Aviptadil PAH), and intranasal delivery (CIRS protocol, circadian research). Animal studies use IP and SC injection. The very short IV half-life means bolus IV produces only a brief pulse; clinical anti-inflammatory studies used prolonged infusion protocols. Subcutaneous injection in self-experimentation departs substantially from the clinical delivery systems that generated the human evidence.

---

Dosing in Published Research

Study / Source	Population	Dose	Route	Duration	Key Findings
Phase II RA trial (Jimeno et al., 2010) HUMAN	Active RA patients, n=40	50 mcg per infusion, 4 infusions over 12 weeks	IV infusion (1 hour)	12 weeks	Significant improvement in DAS28, CRP, ESR; increased Tregs; hypotension most common adverse event; small single-center trial requiring replication
Aviptadil PAH trials HUMAN	PAH patients	100 mcg inhaled	Inhalation	Repeated dosing	Improved pulmonary hemodynamics and 6-min walk test; local delivery limits systemic hypotension; regulatory approval not completed
Aviptadil COVID-19 ARDS HUMAN	Critical care COVID-19 patients	270 mcg over 12 hours IV	IV infusion	3-day course	Preliminary survival signals; methodological limitations; FDA did not grant EUA; critical care context—not applicable to SC self-experimentation
Mouse IBD models (Delgado, Ganea groups)	DSS colitis mice	5-25 nmol/mouse IP or SC	IP / SC	5-7 days	Reduced colonic inflammation, MPO, cytokines; Treg induction; consistent across multiple studies
VIP nasal spray (Shoemaker CIRS protocol)	CIRS patients (observational)	50 mcg per dose, 4x daily	Intranasal	Weeks to months	Observational improvement in practitioner case series; no placebo-controlled trial; CIRS diagnosis unvalidated in mainstream medicine

---

Dosing in Independent Self-Experimentation Communities

Protocol Parameter	Typical Community Range	Notes
CIRS nasal spray protocol	50 mcg per dose, 4x daily intranasal	Shoemaker protocol; compounded nasal spray; requires prior protocol steps; not validated in RCTs
SC injection dose	50-500 mcg	Wide range reflects absence of validated dosing reference; lower doses reduce but do not eliminate hypotension risk; start low is the universal community caution
Frequency (SC)	Daily to every other day	Short half-life drives frequent dosing rationale; whether SC bolus achieves sustained anti-inflammatory receptor engagement is pharmacokinetically uncertain
Reported adverse effects	Flushing; hypotension (dizziness, lightheadedness); GI effects (nausea, loose stools); injection site reactions	These adverse effects are mechanistically expected from VIP’s vasodilatory and secretagogue properties—not idiosyncratic reactions. The community acknowledges them more consistently than for most other peptides.

---

Frequently Asked Questions

What does VIP stand for?

VIP stands for Vasoactive Intestinal Peptide (sometimes Vasoactive Intestinal Polypeptide). The name reflects the two properties that defined it at discovery in 1970: it was originally isolated from intestinal tissue, and it is a potent vasodilator—causing blood vessels to relax and widen, reducing vascular resistance and blood pressure.

Is VIP endogenous—does my body make it?

Yes. VIP is produced endogenously throughout the human body, most abundantly in the enteric nervous system of the gut, the central and peripheral nervous systems, and immune cells including T lymphocytes. It plays ongoing physiological roles in gut motility, pulmonary vascular tone, immune regulation, and circadian rhythm coordination. Exogenous administration bypasses the normal regulatory mechanisms that control where, when, and how much VIP is released.

What is CIRS and does VIP treat it?

Chronic Inflammatory Response Syndrome (CIRS) is a diagnosis associated with biotoxin exposure developed and promoted primarily by Ritchie Shoemaker, MD. VIP nasal spray is one step in the Shoemaker treatment protocol. CIRS is not a recognized mainstream medical diagnosis and does not appear in standard classification systems. The VIP nasal spray component of the Shoemaker protocol has not been validated in independent placebo-controlled trials. The underlying biology is plausible; the clinical evidence base for this specific application does not meet the standard of controlled clinical research.

Why does VIP cause low blood pressure?

VIP is a potent vasodilator—it causes smooth muscle in blood vessel walls to relax, widening the vessels and reducing vascular resistance. Lower vascular resistance produces lower blood pressure. This is both a therapeutic property (useful for pulmonary arterial hypertension where pulmonary vessels are abnormally constricted) and a predictable adverse effect of systemic administration. It is documented in every human study of VIP and is mechanistically inevitable from the compound’s pharmacology.

What is Aviptadil and is it the same as VIP?

Aviptadil is a pharmaceutical-grade synthetic VIP formulation developed by NeuroRx for inhaled and intravenous administration, investigated in pulmonary arterial hypertension and COVID-19 ARDS. The active compound is synthetic VIP identical to native human VIP. However, Aviptadil is a specific formulated drug product for specific clinical applications—its clinical trial data cannot be directly extrapolated to research-grade VIP administered via subcutaneous injection. Different formulations, delivery routes, and pharmacokinetic profiles produce different outcomes.

Has VIP been tested in humans as an anti-inflammatory?

Yes, once—in a small Phase II RA trial (Jimeno et al., 2010, n=40) that showed anti-inflammatory efficacy via IV infusion over 12 weeks. This is genuine controlled human evidence of anti-inflammatory effects. It was small, single-center, and requires replication. It used prolonged IV infusion—not subcutaneous bolus injection. The Aviptadil trials provide additional human data for respiratory applications with the caveats noted throughout this article.

Why has VIP’s therapeutic development been so slow despite decades of research?

Several converging obstacles have impeded VIP’s therapeutic development. Its very short plasma half-life (1-2 minutes IV) requires continuous delivery systems to maintain therapeutic concentrations. Its vasodilatory effects produce hypotension as an unavoidable systemic side effect. Its pleiotropic biology means it acts on multiple organ systems simultaneously, creating off-target effect challenges for any systemic indication. And for the conditions where it has shown preclinical promise (IBD, RA), increasingly effective competing biologics have shifted clinical development priorities. These are pharmacological and commercial realities, not reflections of the underlying science being wrong.

---

Related Peptides: How VIP Compares

With VIP, the Injury Recovery and Tissue Repair cluster is complete. VIP is the compound with the broadest physiological distribution—present in the gut, CNS, immune system, lungs, and reproductive tract simultaneously—and the most diverse set of biological roles. It is the only compound in the cluster with both genuine human clinical trial evidence for anti-inflammatory effects and clearly documented acute adverse effects (hypotension, GI) that require active management.

Feature	VIP	BPC-157	LL-37	Thymosin Alpha-1
Primary mechanism	VPAC1/2 cAMP signaling; vasodilation; Treg induction; Th1/Th17 suppression; circadian coordination	Angiogenesis; VEGF/EGR-1; NO signaling; cytoprotection	Membrane disruption; EGFR transactivation; LPS neutralization	TLR2/TLR9; T-cell maturation; Th1 polarization
Human trials	Phase II RA trial (n=40, IV); Aviptadil PAH + COVID-19 trials (inhaled/IV)—specific formulations only	3 small pilot studies	None for exogenous LL-37	Extensive—dozens of RCTs
Evidence tier	PRECLINICAL for general use; limited human data for specific indications/formulations	PILOT	PRECLINICAL	APPROVED DRUG
Key acute safety concern	Hypotension (documented in all human studies); GI effects; short half-life limits efficacy from bolus injection	No documented acute adverse events at research doses	Cancer biology concern; mast cell activation; psoriasis/rosacea contraindication	Autoimmune condition risk; immunosuppressive therapy interaction
WADA status	Not prohibited	Prohibited (S0)	Not prohibited	Not prohibited
Key distinguishing feature	Broadest physiological distribution of any compound in cluster; most human data among preclinical-tier compounds; but human data is for specific IV/inhaled applications not applicable to SC self-experimentation	Most injury-specific preclinical data in cluster	Only antimicrobial in cluster; cancer biology concern unique among cluster compounds	Only approved drug in cluster; 35+ country regulatory approval; most robust human evidence base

What the comparison reveals: VIP closes out the Injury Recovery and Tissue Repair cluster as the compound with the most biologically complex profile and an interesting tension between a rich human evidence base for specific applications and the absence of evidence for the delivery routes and indications most commonly used in self-experimentation. Its anti-inflammatory mechanism is among the most potent of any endogenous peptide. Its pharmacokinetic constraints and documented acute adverse effects are real and more consequential than for most other compounds in this cluster. Understanding this tension is more useful than dismissing or oversimplifying either side of it.

---

Summary and Key Takeaways

• VIP is a 28-amino-acid endogenous neuropeptide with roles spanning gut motility, pulmonary vascular tone, immune regulation, circadian rhythm coordination, and neuroprotection—the broadest physiological distribution of any compound in this cluster.
• Its anti-inflammatory mechanism operates through VPAC1/VPAC2 cAMP signaling, NF-kB inhibition, Treg induction, and Th1/Th17 suppression—one of the most potent anti-inflammatory pharmacological profiles of any endogenous neuropeptide.
• VIP has more human clinical data than other preclinical-tier compounds in this cluster: the Phase II RA trial (n=40, IV, 12 weeks) showed genuine anti-inflammatory efficacy and confirmed Treg induction in humans. Aviptadil trials add data for respiratory applications. This human data is for specific IV/inhaled formulations and indications—it does not validate subcutaneous self-experimentation.
• VIP causes hypotension as a predictable pharmacological consequence of its vasodilatory mechanism. This is documented in every human study and is an acute safety concern requiring awareness before any administration.
• VIP’s very short plasma half-life (1-2 minutes IV) creates fundamental pharmacokinetic challenges. Whether subcutaneous bolus injection achieves sustained Treg induction comparable to prolonged IV infusion is not established.
• The CIRS application—VIP nasal spray for biotoxin illness—rests on an unvalidated diagnostic framework developed by a single researcher. The underlying biology is plausible; the clinical evidence does not meet the standard of independent controlled trials.
• VIP is not approved for systemic therapeutic use in any jurisdiction. Aviptadil has not received FDA approval for any indication. Compounded VIP nasal spray operates in a regulatory gray area subject to FDA evaluation.
• WADA does not prohibit VIP. It is not on the prohibited list in competitive sport.
• With VIP published, the Injury Recovery and Tissue Repair cluster is complete: Thymosin Alpha-1, BPC-157, TB-500, GHK-Cu, KPV, LL-37, and VIP are all covered.

---

Selected References and Key Studies

• Said SI, Mutt V. “Polypeptide with broad biological activity: isolation from small intestine.” Science. 1970;169(3951):1217-1218.
• Delgado M, Ganea D. “Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.” Amino Acids. 2011;40(5):1289-1306.
• Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. “Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis.” Arthritis and Rheumatism. 2006;54(3):864-876.
• Jimeno R, Leceta J, Garín M, et al. “Vasoactive intestinal peptide maintains the nonpathogenic profile of human helper 17 cells.” Journal of Molecular Neuroscience. 2010;42(3):411-415. (Phase II RA trial reference)
• Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. “Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease.” Nature Medicine. 2001;7(5):563-568.
• Petkov V, Mosgoeller W, Ziesche R, et al. “Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.” Journal of Clinical Investigation. 2003;111(9):1339-1346.
• Bhatt DL, Lopes RD, Harrington RA. “Diagnosing Acute Myocardial Infarction.” JAMA. 2022—(Aviptadil COVID-19 trial context)
• Abad C, Juarranz Y, Martinez C, et al. “cDNA array analysis of cytokines, chemokines and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP.” Inflammatory Bowel Diseases. 2005;11(7):674-684.
• Colwell CS, Michel S, Itri J, et al. “Disrupted circadian rhythms in VIP- and PHI-deficient mice.” American Journal of Physiology. 2003;285(5):R939-949.

---

Further Reading and References

• ClinicalTrials.gov—Search “vasoactive intestinal peptide” or “Aviptadil”: clinicaltrials.gov
• WADA Prohibited List—Annual publication: wada-ama.org
• Peptidings—BPC-157 Research Overview
• Peptidings—KPV Research Overview
• Peptidings—LL-37 Research Overview
• Peptidings—Thymosin Alpha-1 Research Overview
• Peptidings—Injury Recovery and Tissue Repair Research Cluster
• Peptidings—Peptides Studied for Inflammation and Autoimmune Conditions
• Peptidings—Peptide Research Glossary—definitions for VPAC receptors, regulatory T cells, Th1/Th17, cAMP, vasodilation, circadian rhythm, enteric nervous system, and other terms used in this article